Observation and analysis of the clinical effect of Ambroxol combined with azithromycin in the treatment of the children with mycoplasma pneumonia

Objective To explore the clinical effect of Ambroxol combined with azithromycin in the treatment of the children with mycoplasma pneumonia, and to analyze its effect on lung function. Methods 196 children patients with mycoplasma pneumonia from January 2013 to April 2014 in the Sixth Hospital of Ningbo City were randomly selected,they were divided into intervention group and control group according to the treatment methods. 95 patients of the control group, were treated with azithromycin on the basis of conventional therapy, 101 patients in the intervention group,were treated with Ambroxol combined with azithromycin. the therapeutic effect and lung function changes after a treatment course, the forced vital capacity(FVC), forced expiratory volume in one second(FEV1), peak expiratory flow rate(PEF), forced expiratory flow rate of 25%(MEF25), forced expiratory flow rate of 50%(MEF50) were observed, and the main symptoms and signs disappeared time and adverse reaction results during the treatment period were observed.Results The total effective rate of the intervention group was 96.05%(96/101), more than that of control group [86.32%(82/95)], there was significant difference statistically between two groups(P 0.05). The ineffective rate of patients in the intervention group was 4.95%(5/101), lower than that of the control group [13.68%(13/95)], there was significant difference statistically between two groups(P 0.05). FVC, FEV1, PEF, MEF25 and MEF50 of the intervention group were(88.31±6.16) %,(84.14±5.32) %,(85.29±6.02) %,(71.36±4.62) % and(69.28±4.16) % respectively, higher than those of the control group [(82.19±5.22) %,(80.31±4.94) %,(81.43±4.17) %,(64.08±3.88) %,(63.10±3.91) %], the differences were statistically significant(P 0.05). The cough disappeared time, lung inflammation absorption, pulmonary rales disappearance time and treatment time of the intervention group were(2.31±0.72) d,(6.04±2.11) d,(5.94±1.68) d and(7.96 ±1.38) d respectively, lower than those of the control group [(6.05 ±0.76),(8.51 ±2.08),(8.26 ±2.06),(9.32±2.75) d], the differences were statistically significan(P 0.05). The patients' adverse reactions of two groupsshowed no significant difference(P 0.05). Conclusion There is a better effect of Ambroxol combined with azithromycin for treatment of mycoplasma pneumonia of children, which can improve the lung function and shorten the treatment time of patients significantly obviously.